GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » ROC (Joel Greenblatt) %

Cardiol Therapeutics (TSX:CRDL) ROC (Joel Greenblatt) % : -9,059.52% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cardiol Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9,059.52%.

The historical rank and industry rank for Cardiol Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

TSX:CRDL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12679.75   Med: -8421.05   Max: -245.19
Current: -9443.88

During the past 7 years, Cardiol Therapeutics's highest ROC (Joel Greenblatt) % was -245.19%. The lowest was -12679.75%. And the median was -8421.05%.

TSX:CRDL's ROC (Joel Greenblatt) % is ranked worse than
98.78% of 1062 companies
in the Drug Manufacturers industry
Industry Median: 7.875 vs TSX:CRDL: -9443.88

Cardiol Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -122.50% per year.


Cardiol Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cardiol Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics ROC (Joel Greenblatt) % Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -245.19 -597.80 -9,250.00 -12,679.75 -9,411.06

Cardiol Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,523.24 -10,398.66 -8,832.17 -9,555.07 -9,059.52

Competitive Comparison of Cardiol Therapeutics's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiol Therapeutics's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's ROC (Joel Greenblatt) % falls into.



Cardiol Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.178 + 0 + 1.62) - (7.191 + 0 + 0.81)
=-6.203

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.143 + 0 + 0.941) - (8.041 + 0 + 0.238)
=-7.195

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cardiol Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-32.116/( ( (0.372 + max(-6.203, 0)) + (0.337 + max(-7.195, 0)) )/ 2 )
=-32.116/( ( 0.372 + 0.337 )/ 2 )
=-32.116/0.3545
=-9,059.52 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiol Therapeutics  (TSX:CRDL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cardiol Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiol Therapeutics (TSX:CRDL) Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Executives
Guillermo Torre Senior Officer

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 07-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 05-24-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-23-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-13-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired 02-20-2019

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-03-2022